Hegseth Responded Perfectly to the Libs' Uproar Over Our Air Campaign Against Narco-Terror...
Ken Dilanian Ignores Official Statements to Report Rumors, and Jake Tapper Assumes Race...
Yes, Richard Gere, Illegal Immigrants Are (D)ifferent
Crooks, Disguised As 'Protectors,' Are Still on the Loose
Time for a Midterm Contract With America
Democrats Fuel Racial Strife to Get Votes
Supreme Court Should Not Let Climate Lawfare Set US Energy Policy
Trump’s Not the First to Invoke Old Laws
Panic-Stricken Climate Alarmists Resort to Bolder Lies
Fear and Ideological Conformity Cannot Win on College Campuses
America Did Not Owe the Afghan National Who Murdered Sarah Beckstrom Resettlement...
Two Illinois Brothers Indicted in $293M COVID Testing Fraud Scheme
Woman Charged With Smuggling Aliens Through Canada
Maxine Waters Calls Trump a Killer For Destroying NarcoTerrorists
ATMs Help Trace $250K Unemployment Fraud Scheme to Michigan Government Employee and Partne...
Tipsheet

The CDC Director Just Gave Us an Updated Vaccine Timeline

AP Photo/Alex Brandon

We've brought you a lot of exciting vaccine news these past few weeks. And there's more of it on Tuesday. Center for Disease Control Director Robert Redfield said Americans should expect a vaccine to be rolled out very, very soon. He predicted the second week of December.

Advertisement

The next question then is, who will be receiving the first doses. He answered that too.

In an interview with Fox News anchor Dana Perino, Redfield shared that the first groups to get the vaccine will probably be "nursing home residents and then some combination of health care providers and individuals at high risk for a poor outcome."

"I do think we'll have about 40 million doses of vaccine before the end of the...year," Redfield continued. "That's enough to vaccinate 20 million people. But then it will continue through January and February and hopefully by March we'll start to see vaccine available for the general public."

Advertisement

Pfizer, who vaccine its been developing with BioNTech has produced a 95 percent efficacy rate, requested an emergency authorization from the FDA. A second vaccine candidate being produced by Moderna isn't too far behind, reporting a 94 percent effectiveness. And then a third, developed by AstraZeneca, is up to 90 percent effective.

The FDA has reportedly scheduled a meeting for Dec. 10 with its Vaccines and Related Biological Products Advisory Committee to discuss Pfizer's request.

Join the conversation as a VIP Member

Recommended

Trending on Townhall Videos